Skip to main content

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Recruiting · Phase 2 · NCT06855771

Conditions: Carcinoma, Non-Small-Cell Lung

At a glance

Research payments reported, 2025
$43,736
U.S. investigators named
26
Sites paid
25
Planned or actual enrollment
182

About the trial

Sponsor
Bristol-Myers Squibb
Tested
BMS-986504 (drug), Izalontamab Brengitecan (drug)
Dates
Started 2025-09-09; completion 2031-12-30
Results posted
Not yet

The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on prior therapies.

From ClinicalTrials.gov, last updated 2026-09-18. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $43,736 in research payments for this study in 2025 (29 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.